Red Dye 3 vs Potassium Bromate: which is worse?

What is Red Dye 3?

Red Dye 3 (erythrosine) is a synthetic cherry-pink fluorescent dye belonging to the xanthene class. It contains approximately 58% iodine by weight, distinguishing it from azo dyes. Its chemical formula is C20H6I4Na2O5. Approved since 1907, it is one of the oldest certified US food colorants and was notably the first synthetic food dye formally revoked by the FDA in decades.

What is Potassium Bromate?

Potassium bromate (KBrO3) is an oxidizing agent used in commercial bread baking as a flour maturing agent and dough conditioner. It strengthens gluten networks, improves dough elasticity, and produces a more uniform, light-textured baked product. It is a white crystalline powder.

Documented risks

Red Dye 3: The FDA revoked Red Dye 3 authorization in January 2025, marking the first synthetic food dye ban by the FDA since Red Dye 2 in 1976. The revocation was triggered by the Delaney Clause, which mandates revocation of any food additive found to cause cancer in animals regardless of dose. The carcinogenicity data stems from studies showing that high doses of erythrosine caused thyroid follicular cell tumors in male rats. The mechanism is indirect: erythrosine suppresses thyroid-stimulating hormone (TSH) feedback by elevating thyroxine (T4) levels, causing chronic TSH suppression that promotes thyroid cell proliferation and ultimately tumor formation. This is a rat-specific mechanism related to their thyroxine-binding protein system, which differs from human biology. EFSA's 2011 comprehensive safety assessment concluded erythrosine was unlikely to be genotoxic at typical food use levels and set an ADI of 0.1 mg/kg body weight — one of the lowest for any food color. EFSA restricted EU use to cocktail cherries only (max 200 mg/kg). The high iodine content (58% by weight) raises concerns for thyroid-sensitive individuals. Excessive erythrosine intake could theoretically contribute to iodine overload and thyroid disruption, particularly in individuals with hyperthyroidism or Hashimoto's disease. The FDA had been aware of the rat thyroid tumor data since 1990 but delayed action for 35 years. Advocacy groups including CSPI petitioned for a ban since 1983. The January 2025 revocation finally addressed this long-standing regulatory gap.

Potassium Bromate: Potassium bromate is classified by the International Agency for Research on Cancer (IARC) as Group 2B — a possible human carcinogen — based on sufficient evidence in animals. This classification was formalized in 1999. The landmark toxicology study is Kurokawa et al. (1990), published in Environmental Health Perspectives (PMC1567851), which demonstrated that KBrO3 induces renal cell tumors (kidney cancer), mesotheliomas of the peritoneum, and follicular cell tumors of the thyroid in rats. Importantly, the researchers demonstrated KBrO3 is a complete carcinogen — it possesses both tumor-initiating and tumor-promoting activities for renal tumorigenesis. The mechanism of carcinogenicity involves generation of reactive oxygen species, particularly hydroxyl radicals and superoxide radicals. These radicals cause oxidative DNA damage, specifically 8-hydroxydeoxyguanosine (8-OHdG) formation in rat kidney cells — a well-characterized biomarker of oxidative DNA damage. California declared potassium bromate a known carcinogen under Proposition 65 in 1991, requiring cancer warning labels on California products containing it. Multiple advocacy organizations including CSPI (1999 petition) and EWG (2015 petition) have petitioned the FDA for a federal ban. As of 2025, the FDA has urged voluntary industry elimination since the early 1990s but has not issued a formal ban. Nephrotoxicity from high-dose potassium bromate is well documented in case reports of accidental or intentional poisonings: it causes irreversible renal tubular necrosis, permanent deafness (cochlear damage), and blindness (optic nerve damage). These effects occur at doses far above food consumption scenarios but demonstrate the compound's acute toxicological potency. FDA testing in 1999 found residual potassium bromate above expert-recommended safe limits in more than half of 17 tested bread and roll products, demonstrating that the 'it bakes off completely' argument does not always hold in commercial practice.